Premium
Effect of MAO‐B Inhibitors on MPP + Toxicity in Vivo
Author(s) -
WU RUEYMEEI,
CHEN RONGCHI,
CHIUEH CHUANG C.
Publication year - 2000
Publication title -
annals of the new york academy of sciences
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.712
H-Index - 248
eISSN - 1749-6632
pISSN - 0077-8923
DOI - 10.1111/j.1749-6632.2000.tb06191.x
Subject(s) - neuroprotection , selegiline , monoamine oxidase b , mptp , chemistry , pharmacology , dopamine , pargyline , monoamine oxidase , toxicity , oxidative stress , parkinsonism , in vivo , parkinson's disease , dopaminergic , biochemistry , enzyme , neuroscience , medicine , biology , disease , organic chemistry , microbiology and biotechnology
A bstract :l ‐Deprenyl (Selegiline), a selective and irreversible type B monoamine oxidase inhibitor, has been used as an adjunct to levodopa therapy in Parkinson's disease. Recently, it is proposed as a putative neuroprotective agent in delaying the progression of cell death based on its capability of reducing the oxidative stress derived from the MAO‐B dependent metabolism of dopamine, and blocking the development of MPTP‐parkinsonism. However, a variety of experimental models suggest that l ‐deprenyl provides neuroprotection through multiple modes of mechanism other than the inhibition of MAO‐B. We have previously shown that l ‐deprenyl protects midbrain dopamine neurons from MPP+ toxicity by a novel antioxidant effect. In the present study we examined whether the protection against MPP+ toxicity is also shared by other reversible or irreversible MAO‐B inhibitors including (+)‐deprenyl, Ro16‐6491 and pargyline. Our data show that non of these MAO‐B inhibitors changes the dopamine loss in the striatum induced by intranigral injection of MPP+. Our result suggests that l ‐deprenyl may possess a unique neuroprotective action on nigral neuron against MPP+ toxicity independent of the MAO‐B inhibition.